US4940694A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic use of GM1 in severe cerebral ischemic strokes pathologies
Assignee: Fidia SpA
•
Filing: 1988-10-20
•
Granted: 1990-07-10
•
Expires: 2008-10-20
Abstract
Abstract A pharmaceutical preparation containing the ganglio-side GM1 or an inner ester derivative thereof and a method for increasing cerebral blood flow in stroke victims by acute administration of GM1 or its inner ester derivative.
Inventors
- 👤 Francesco Della Valle
- 👤 Aurelio Romeo
- 👤 Silvana Lorenzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 02:44
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; C07H15/10; A; A61; A61P; A61P25/00; A61P25/28; A61P9/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
35 words
A method for the treatment of cerebral stroke patients which comprises administering to said patients an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt of said ganglioside GM 1 .
Claim 2
Independent Claim
35 words
A method for the treatment of cerebral stroke patients which comprises administering to said patients an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt of said ganglioside GM 1 .
Claim 3
Independent Claim
36 words
A method for increasing cerebral blood flow and preventing neuronal death, which comprises administering an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt thereof to patients in need of such treatment.
Claim 4
Independent Claim
36 words
A method for increasing cerebral blood flow and preventing neuronal death, which comprises administering an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt thereof to patients in need of such treatment.
Claim 5
Independent Claim
41 words
A method for increasing cerebral blood flow in stroke patients and preventing neuronal death, without undesirably altering arterial blood pressure which comprises administering to said patients an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt thereof.
Claim 6
Independent Claim
41 words
A method for increasing cerebral blood flow in stroke patients and preventing neuronal death, without undesirably altering arterial blood pressure which comprises administering to said patients an effective amount of the ganglioside GM 1 , or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
25 words
A method according to claim 1, wherein said ganglioside GM 1 is administered to said patient within seven days after the occurrence of a stroke.
Claim 8
Dependent Claim
25 words
A method according to claim 1, wherein said ganglioside GM 1 is administered to said patient within two days after the occurrence of a stroke.
References Cited (Backward Citations)
US4415733A
Cited
US4435389A
Cited
EP0072722A2
Cited
US4476119A
Cited
US4521593A
Cited
US4631294A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-07-09 | 1994-01-08 | 1994-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-07-09 | 1998-01-08 | 1998-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-07-09 | 2002-01-08 | 2002-07-10 | $7700.00 | Window Closed / Lapsed |